Minomic International Ltd is an Australian immuno-oncology company that has developed an in vitro diagnostic test for the early detection of prostate cancer. The test, known as MiCheck® detects biomarkers present in the blood of patients. A series of clinical trials have shown MiCheck® gives much more accurate results than existing blood tests for prostate cancer. MiCheck® fills a major need in prostate cancer diagnostics to follow on reported high PSA levels and better triage patients by differentiating aggressive cancer from non-aggressive or no cancer before invasive and expensive biopsies. We have formed a partnership with Cirrus Dx (US) to offer MiCheck® as a Laboratory Developed Test (LDT) available through their CLIA certified laboratory.